Drug Profile

ATL 201 - Atalanta Therapeutics

Alternative Names: ATL-201-Atalanta Therapeutics

Latest Information Update: 17 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Atalanta Therapeutics
Class Antiepileptic drugs; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Epilepsy

Most Recent Events

08 Apr 2025 Atalanta Therapeutics plans to submit an Investigational New Drug (IND) application to the US FDA for ATL 201 in Epilepsy in USA, in 2025
08 Apr 2025 Pharmacodynamics and safety data from preclinical trials in Epilepsy released by Atalanta Therapeutics
28 Jan 2025 Preclinical trials in Epilepsy in USA (Parenteral) prior to January 2025

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com